

AASK PROTOCOL

TABLE OF CONTENTS AND DATES OF REVISIONS

May 17, 2001

	<u>Page Number</u>
1. INTRODUCTION	1001
1.a. Background	1001
1.b. Scope of the Problem.....	1001
1.c. Unique Aspects of Hypertensive ESRD in African Americans.....	1001
1.d. Renal Structure in Relation to Function in African American Hypertensive	1002
1.e. Evidence for the Renoprotective Effects of BP Control.....	1002
1.f. What Degree of BP Control is Beneficial?	1003
1.g. Are Specific Antihypertensives Selectively Renoprotective?.....	1004
1.h. Effects of Specific Antihypertensive Agents on Renal Hemodynamics	1006
1.i. Goals of the AASK Full Scale Study	1007
1.j. Timeline: Month 1 to 88.....	1008
1.k. Patient Timeline	1008
1.l. Documentation: Protocol, Manual and Forms	1009
1.m. Training and Certification.....	1009
<i>All pages in Section 1 are dated December 9, 1997</i>	
2. OBJECTIVES AND DESIGN	2001
2.a. Objectives.....	2001
2.b. Design.....	2001
2.c. Antihypertensive Medication Treatment Arms.....	2002
2.d. Length of Time for Screening/Baseline in the Full-Scale Study	2003
2.e. Sample Size in the Full-Scale Study.....	2004
<i>All pages in Section 2 are dated May 23, 1997</i>	
3. PARTICIPANT SELECTION/ELIGIBILITY & EXCLUSION CRITERIA	3001
3.a. Inclusion Criteria.....	3001
3.b. Exclusion Criteria	3001
<i>All pages in Section 3 are dated May 23, 1997</i>	
4. INFORMED CONSENT	4001
4.a. General Principles of Consent	4001
4.b. Participation in Other Studies	4001
4.c. Sequence of Consent Procedures.....	4001
4.d. Privacy.....	4002
<i>All pages in Section 4 are dated March 8, 1995</i>	

5.	SCREENING PERIOD EVALUATION	5001
5.a.	General Principles of Screening	5001
5.b.	Recruitment Strategy.....	5001
5.c.	Screening Period Eligibility Requirements	5001
5.d.	Screening Procedure	5001
5.e.	Restarting Baseline	5002
5.f.	Creatinine Eligibility When Entering Baseline	5003
5.g.	Evaluation of Recruitment, Screening, Retention and Compliance	5004

All pages in Section 5 are dated May 23, 1997

6.	CLINICAL CENTER MEASUREMENTS AND PROCEDURES DURING SCREENING, BASELINE AND FOLLOW-UP	6001
6.a.	General Procedures	6001
6.b.	Glomerular Filtration Rate.....	6001
6.c.	24-hour Urine Collections	6001
6.d.	Arterial Blood Pressure.....	6002
6.e.	Blood Tests	6003
6.f.	Electrocardiograms	6003
6.g.	Questionnaires.....	6004

All pages in Section 6 are dated May 23, 1997

7.	ANTIHYPERTENSIVE REGIMENS	7001
7.a.	Introduction	7001
7.b.	Blood Pressure (MAP) Goals for the Follow-up Period.....	7001
7.c.	General Principles of Blood Pressure Management.....	7002
7.d.	Protocol Compliance.....	7003
7.e.	BP Compliance: Management of Participants with MAP Above Randomized Goal	7004
7.f.	BP Compliance: Management of Participant with MAP Below Randomized Goal	7006
7.g.	Early Termination of the Calcium Channel Blocker Arm.....	7007

All pages in Section 7 are dated January 16, 2001

8.	BASELINE PERIOD EVALUATION	8001
8.a.	General Principles of Baseline.....	8001
8.b.	Glomerular Filtration Rate.....	8002
8.c.	Laboratory Tests from Screening through Randomization.....	8003
8.d.	Screening Medication Status	8005
8.e.	History and Physical Examination.....	8005
8.f.	Blood Pressure Measurement	8005
8.g.	Participant Questionnaires	8006
8.h.	Treatment of Hypertension during Baseline Period.....	8006
8.i.	Randomization	8007
8.j.	Assessment of Compliance to Study Protocol	8007
8.k.	Additional Assessments and Exclusions during the Baseline Period.....	8008

All pages in Section 8 are dated May 23, 1997

9.	RANDOMIZATION PROCEDURE	9001
----	--------------------------------------	------

All pages in Section 9 are dated October 1, 1996

10.	FOLLOW-UP PERIOD EVALUATION	10001
10.a.	General Principles of Follow-Up.....	10001
10.b.	Glomerular Filtration Rate Details	10001
10.c.	Laboratory Tests in Follow-Up.....	10001
10.d.	Follow-Up 24-Hour Urine Collections Details	10002
10.e.	Follow-Up Blood Test Details.....	10002
10.f.	ECG Details	10004
10.g.	Drug Therapy	10004
10.h.	History and Physical Examination.....	10004
10.i.	Participant Questionnaires	10005
10.j.	Interim Visits.....	10005
10.k.	Lifestyle Modifications	10005
10.l.	Educational Materials Regarding Diet	10006
10.m.	Hypercholesterolemia	10006
10.n.	Cigarette Addiction.....	10007
10.o.	Ethanol Consumption	10007
10.p.	Missed Visit or Measurement.....	10007
10.q.	Patient Transfers	10007
10.r.	Close Out and Post Close Out	10007
10.s.	Follow-Up After Confirmed Dialysis Stop Point.....	10008

All pages in Section 10 are dated December 9, 1997

11.	DEVIATIONS FROM ASSIGNED TREATMENT	11001
11.a.	Action Items	11001
11.b.	Adverse Events, Hospitalizations, and Deaths.....	11007
11.c.	Stop Points	11008

All pages in Section 11 are dated June 29, 1999

12.	ANALYSIS PLAN	12001
-----	----------------------------	-------

12.a.	Baseline Analyses	12001
12.b.	Analyses During Follow-Up.....	12001
12.c.	Primary Renal Function Analysis.....	12002
12.d.	Secondary Patient-Outcome Analysis	12004
12.e.	Explanatory Renal Function Analyses	12005
12.f.	Explanatory Analyses Related to Time-to-Event.....	12007
12.g.	Power of Primary Analyses	12009
12.h.	Interim Analyses	12014
12.i.	Cardiovascular Analyses.....	12014

All pages in Section 12 are dated May 3, 1999

13.	QUALITY CONTROL	13001
13.a.	Quality Control Introduction	13001
13.b.	Quality Control of Clinical Centers.....	13001
13.c.	Quality Control of the Central Biochemistry Laboratory.....	13005
13.d.	Quality Control of the Central GFR Laboratory	13006
13.e.	Quality Control of the Data Coordinating Center	13006

All pages in Section 13 are dated May 15, 1998

14.	ADMINISTRATIVE STRUCTURE	14001
14.a.	Administrative Structure National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK)	14001
14.b.	Administrative Committees.....	14002
14.c.	Other Committees	14003
14.d.	The Clinical Centers	14006
14.e.	The Data Coordinating Center (DCC).....	14006
14.f.	The Drug Distribution Center.....	14007
14.g.	The Central GFR Laboratory	14007
14.h.	The Central Laboratory for Biochemistries and 24-Hour Urines	14008

All pages in Section 14 are dated October 5, 1996

15.	PROTOCOL CHANGES	15001
15.a.	General Principles of Protocol Change	15001
15.b.	Protocol Change Procedures.....	15001

All pages in Section 15 are dated March 8, 1995

16.	ANCILLARY STUDIES	16001
16.a.	Ancillary Studies Definition	16001
16.b.	Funding of Ancillary Studies.....	16001
16.c.	Approval Procedures for Ancillary Studies.....	16001
16.d.	Guidelines for Genetic Ancillary Studies.....	16002
16.e.	Publication of Ancillary Study Results	16002

All pages in Section 16 are dated May 31, 1995

17.	MAINTENANCE AND DISPOSITION OF STUDY DOCUMENTS DATA AND MATERIALS	17001
-----	--	-------

17.a.	Introduction	17001
17.b.	Internal Distribution of Study Documents	17001
17.c.	External Distribution of Study Documents	17001
17.d.	Data Collection Forms	17001
17.e.	Data Tapes and Analysis of Results	17001
17.f.	Laboratory Specimens and Materials	17002

All pages in Section 17 are dated October 5, 1996

18.	SCHEDULE OF PARTICIPANT EVENTS	18001
18.a.	Screening Period (Visits SV-1,SV-2) Schedule	18001
18.b.	Baseline Period Schedule	18001
18.c.	Consent (Visit CV)	18001
18.d.	Randomization	18001
18.e.	Follow-up (Visits FV-1...FV-n).....	18002
	Table 18.1 Frequency and Visit for Study Procedures and Laboratory Tests during the Screening and Baseline Periods	18003
	Table 18.2 Frequency and Visit for Study Procedures and Laboratory Tests during the Post-Randomization Period.....	18004

All pages in Section 18 are dated May 23, 1997

19.	PUBLICATIONS AND PRESENTATIONS POLICY	19001
19.a.	Introduction	19001
19.b.	Scope of Policy, and Exception for Local Publicity Materials	19001
19.c.	Source of Suggestions for Publications of the AASK Study	19002
19.d.	Assignment of Writing Committees.....	19002
19.e.	Classes of Reports of the AASK Study.....	19003
19.f.	Authorship Policy	19003
19.g.	Listing of Professional Participants in the AASK Participant Box	19004
19.h.	Acknowledgement of Support and Reprint Addresses	19005
19.i.	Schedule of Completion of Writing Assignments and Resolution of Overlaps Between Writing Committees.....	19005
19.j.	Review of Abstracts and Presentations by the PAS Subcommittee	19005
19.k.	Review of Papers by the PAS Subcommittee	19006
19.l.	Criteria for Review of Materials by the PAS Subcommittee.....	19008
19.m.	Maintenance of Records of Publications and Presentations	19008
19.n.	Acknowledgement and Acceptance of AASK Policies on Publications and Presentations by the Professional Participants in the AASK Study	19009

All pages in Section 19 are dated March 8, 1995

20.	REFERENCES	20001
-----	-------------------------	-------

All pages in Section 20 are dated March 8, 1995

21.	GLOSSARY OF ABBREVIATIONS	21001
-----	--	-------

All pages in Section 21 are dated March 8, 1995

22. **INDEX**.....22001
All pages in Section 22 are dated May 23, 1997